TYPESTATUS PLUS 11.3 UPGRADE
TYPESTATUS PLUS 11.3 SERIES
TYPESTATUS PLUS 11.3 FREE

However, 58–73% of the patients with stage I and about 40% of those with stage II disease relapse after surgery, which reduces their 5-year survival rates ( Liang and Wakelee, 2013 Gao et al., 2020). Surgical resection remains the preferred treatment modality for the patients with early-stage NSCLC ( Postmus et al., 2017). In clinical practice, only a small percentage of the patients with NSCLC are diagnosed at an early stage, while the majority of them present with locally advanced or metastatic disease at diagnosis, which accounts for their low five-year survival rate of 4–17% ( Carbone et al., 2015 Hirsch et al., 2017 Osmani et al., 2018). The lung cancer is one of the most frequent malignant tumors, and ranks first in the incidence and mortality among all the cancer types globally ( Bray et al., 2018). Finally, based on the results of the first-line recent trials, we propose a potential first-line immunotherapeutic strategy for the treatment of the patients with NSCLC. In this review, we have reviewed the history of the continuous developments in cancer immunotherapy, summarized the mechanism of action of the immune-checkpoint pathways. On the other hand, there are continuous efforts to find biomarkers that effectively predict the response of ICIs to screen suitable populations. However, controversies remain regarding the use of ICIs in a subgroup with targeted oncogene mutations is a problem that we need to solve.

TYPESTATUS PLUS 11.3 SERIES

Additionally, a series of inhibitors related to PD-1/PD-L1 immune-checkpoints have helped in the immunotherapy of NSCLC patients, and modified the original treatment model. Since March 2015, the US Food and Drug Administration (FDA) approved nivolumab (anti-PD-1 antibody) as the second-line option for treatment of patients with advanced squamous NSCLC.

There are already ICIs targeting different pathways, including the programmed cell death 1 (PD-1), programmed cell death ligand 1 (PD-L1), and cytotoxic T lymphocyte antigen 4 (CTLA-4) pathway. Immune checkpoint inhibitors (ICIs) can act on the inhibitory pathway of cancer immune response, thereby restoring and maintaining anti-tumor immunity. Most of these patients with non-small cell lung cancer (NSCLC) present with the advanced stage of the disease at the time of diagnosis, and thus decrease the 5-year survival rate to about 5%. Lung cancer is one of the most common cancers and the leading cause of cancer-related deaths worldwide.

2Department of Ultrasound, First Affiliated Hospital of Jinzhou Medical University, Jinzhou, China.

1Department of Thoracic Surgery, Affiliated Hospital of Qingdao University, Qingdao, China.

What do you think about these surprise revelations? Are you excited about the idea of having such a major TypeStatus upgrade? Sound off down below in the comments, and stay-tuned for our hands on walkthrough.Zhangfeng Huang 1, Wenhao Su 1, Tong Lu 1, Yuanyong Wang 1, Yanting Dong 1, Yi Qin 1, Dahai Liu 1, Lili Sun 2 and Wenjie Jiao 1*

Version 1.3 is currently in the works, and contains large portions of rewritten code.

TYPESTATUS PLUS 11.3 FREE

But don’t fret, because from the looks of things, the project seems to be shaping up for a public release in the very near future.Īs a side note, the free version of TypeStatus will be receiving some updates as well. TypeStatus Plus is currently in a closed beta period, and unfortunately, the team isn’t taking on any additional beta testers.

TYPESTATUS PLUS 11.3 UPGRADE

It appears to be a well thought-out and feature packed upgrade over the original TypeStatus. Needless to say, TypeStatus Plus looks to be very worthy of its “plus” designation. What about Pebble watch support? Yep, you’ll find that in TypeStatus Plus as well… How about customizable status bar notifications? That’s there too. It also features Notification Center integration and Lock screen integration. It works with WhatsApp, Facebook, Skype, and Kik. Why the Plus? For starters, it works with more than just iMessage. Hashbang productions, the team that brought my idea of TypeStatus to reality, has teased an incoming new version of its popular jailbreak tweak called TypeStatus Plus.

Typestatus plus 11.3